Overview

TCR-engineered T Cells in Solid Tumors

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The study purpose is to establish the safety and tolerability of IMA203 product with or without combination with atezolizumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

Phase:

Phase 1

Details

Lead Sponsor:

Immatics US, Inc.

Treatments:

Atezolizumab